Manajemen Farmakologis Penyakit Hati Berlemak Non-Alkoholik (NAFLD) dalam Upaya Penurunan Prevalensi Penyakit Ginjal Kronis: Tinjauan Sistematis Perspektif Epidemiologi Terapan
DOI:
https://doi.org/10.54259/sehatrakyat.v5i2.7144Keywords:
Diabetes Mellitus, Liver Fibrosis, NAFLD, SGLT2 Inhibitors, Metabolic DiseaseAbstract
Non-alcoholic fatty liver disease (NAFLD) is a global health problem frequently associated with diabetes mellitus and obesity. This condition increases the risk of renal dysfunction and liver fibrosis progression, highlighting the need for comprehensive therapeutic strategies. This study aimed to evaluate the medium-term effects of SGLT2 inhibitors on renal function and fibrosis progression in patients with NAFLD and metabolic diseases. This study employed a brief systematic review approach by analyzing relevant national and international scientific articles. Literature selection was conducted systematically based on predefined inclusion and exclusion criteria. The findings demonstrated that SGLT2 inhibitors were associated with improved or stabilized renal function, particularly in estimated glomerular filtration rate and albuminuria parameters. Moreover, most studies reported improvements in non-invasive fibrosis indicators and reductions in hepatic steatosis and inflammation. These benefits were closely related to better glycemic control and weight reduction in patients with metabolic comorbidities. In conclusion, SGLT2 inhibitors show potential as an adjuvant therapy in managing NAFLD patients with metabolic diseases by providing combined renal and hepatic protective effects.
Downloads
References
Amin, M. A., Sadik, N. A., Saad, H. A., Fawzy, M., & Elsheimy, H. A. (2025). The effect of SGLT2 inhibitors on hepatic steatosis detected by MRI-PDFF in patients with type 2 diabetes mellitus and metabolic-associated steatotic liver disease. Internal and Emergency Medicine, 20, 1025–1033. https://doi.org/10.1007/s11739-025-03902-w
Bae, J. H. (2025). SGLT2 inhibitors and GLP-1 receptor agonists in diabetic kidney disease: Evolving evidence and clinical application. Diabetes & Metabolism Journal, 49, 386–402. https://doi.org/10.4093/dmj.2025.0220
Bai, K., Faizan, M. A., Shakeel, I., Abbas, M. S., Dandamudi, M., Rehman, T., Zahra, I., Mojica, J. C., Ahmed, M. R., Shahzad, Z., & Giorgi, J. (2025). Efficacy of SGLT2 inhibitors in non-diabetic non-alcoholic fatty liver disease: A systematic review and meta-analysis. Journal of Diabetes & Metabolic Disorders, 24, 285. https://doi.org/10.1007/s40200-025-01797-0
Cai, X., Sun, L., Liu, X., Zhu, H., Zhang, Y., Zheng, S., & Huang, Y. (2021). Non-alcoholic fatty liver disease is associated with increased risk of chronic kidney disease. Therapeutic Advances in Chronic Disease. https://doi.org/10.1177/20406223211024361
Deng, N., Soh, K. G., Xu, F., & Yang, X. (2025). The effects of strength and conditioning interventions on serve speed in tennis players: A systematic review and meta-analysis. Frontiers in Physiology, 15, 1469965. https://doi.org/10.3389/fphys.2024.1469965
Grigoriou, K., Karakasis, P., Nasoufidou, A., Stachteas, P., Klisic, A., Karagiannidis, E., Fyntanidou, B., Popovic, D. S., Patoulias, D., & Antoniadis, A. P. (2025). SGLT2 inhibitors in the management of cardio-renal-metabolic syndrome: A new therapeutic era. Medicina, 61(11), 1903. https://doi.org/10.3390/medicina61111903
Hadisuyatmana, S., Boyd, J. H., Efendi, F., Malik, G., Bauer, M., & Reisenhofer, S. (2023). Non-medical and non-invasive interventions for erectile dysfunction in men with type 2 diabetes mellitus: A scoping review. In Heliyon (Vol. 9, Issue 5). Elsevier Ltd. https://doi.org/10.1016/j.heliyon.2023.e15778
Hasan, I., Gani, R. A., Lesmana, C. R. A., & Sulaiman, A. S. (2021). Non-alcoholic fatty liver disease in Indonesia: Current status and challenges. Acta Medica Indonesiana, 53(1), 1–8.
Heyens, L. J. M., Busschots, D., Koek, G. H., Robaeys, G., & Francque, S. (2021). Liver fibrosis in non-alcoholic fatty liver disease: From liver biopsy to non-invasive biomarkers in diagnosis and treatment. Frontiers in Medicine, 8, 615978. https://doi.org/10.3389/fmed.2021.615978
Hirayama, K., Koshizaka, M., Ishibashi, R., Shoji, M., Horikoshi, T., Sakurai, T., & Yokote, K. (2025). Effects of the SGLT2 inhibitor ipragliflozin and metformin on hepatic steatosis and liver fibrosis: sub-analysis of a randomized controlled study. Diabetes, Obesity and Metabolism, 1.
Indonesia, K. K. R. (2023). Profil kesehatan Indonesia tahun 2023. Kementerian Kesehatan Republik Indonesia.
Jones, A. B. (2024). Rethinking Evidence-Based Practice in Education: A Critical Literature Review of the “What Works” Approach Ethical Statement. International Journal of Educational Researchers, 15(2), 37–51. https://doi.org/10.29329/ijer.2024.1041.3
Kacem, I., Moussa, A., Sridi, C., Fki, A., Ajmi, M., Thabet, M., El Maalel, O., Maoua, M., Kahloul, M., & Mrizek, N. (2025). Associations between obesity and the severity of occupational allergic rhinitis: A cross-sectional study. International Journal of Environmental Research and Public Health, 22(10), 1531. https://doi.org/10.3390/ijerph22101531
Kanduri, S. R., Kovvuru, K., Hansrivijit, P., Thongprayoon, C., Vallabhajosyula, S., Pivovarova, A. I., Chewcharat, A., Garla, V., Medaura, J., & Cheungpasitporn, W. (2021). SGLT2 inhibitors and kidney outcomes in patients with chronic kidney disease. Journal of Clinical Medicine.
Kesehatan, B. (2022). Laporan pengelolaan program dan laporan keuangan jaminan sosial kesehatan tahun 2022. BPJS Kesehatan.
Lesmana, C. R. A., Pakasi, L. S., Inggriani, S., Aidawati, M. L., & Lesmana, L. A. (2015). Prevalence of non-alcoholic fatty liver disease in an Indonesian population. Journal of Gastroenterology and Hepatology, 30(Suppl 1), 33–36.
Li, J., Zou, B., Yeo, Y. H., Feng, Y., Xie, X., Lee, D. H., Fujii, H., Wu, Y., Kam, L. Y., Ji, F., Li, X., Chien, N., Wei, M. T., Ogawa, Y., Zhao, C., & Younossi, Z. M. (2022). Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999–2019: A systematic review and meta-analysis. The Lancet Gastroenterology & Hepatology, 7(4), 313–324. https://doi.org/10.1016/S2468-1253(21)00347-0
Liu, H., & Chen, Y. (2024). Behavioral implications of internal control regulation and data governance complexity. International Journal of Accounting Information Systems, 52, 100642.
Lonardo, A., Mantovani, A., Targher, G., & Baffy, G. (2022). Nonalcoholic fatty liver disease and chronic kidney disease: Epidemiology, pathogenesis, and clinical and research implications. International Journal of Molecular Sciences, 23(21), 13320. https://doi.org/10.3390/ijms232113320
Mori, M., Sassetti, S., Cavaliere, V., & Bonti, M. (2024). A systematic literature review on artificial intelligence in recruiting and selection: A matter of ethics. Personnel Review. https://doi.org/10.1108/PR-03-2023-0257
Nabila, S. A., Hasyim, H., Windusari, Y., Novrikasari, & Fajar, N. A. (2024). Analisis Determinan Kejadian Penyakit Kulit Dermatitis Kontak pada Pekerja: Systematic Review. JIKM, 16(2), 101–109.
Ong Lopez, A. M. C., & Pajimna, J. A. T. (2024). Efficacy of sodium glucose cotransporter 2 inhibitors on hepatic fibrosis and steatosis in non-alcoholic fatty liver disease: An updated systematic review and meta-analysis. Scientific Reports, 14, 52603. https://doi.org/10.1038/s41598-024-52603-5
Popoviciu, M. S., Păduraru, L., Rahman, M. M., Supti, F. A., Stoica, R. A., Reurean-Pintilei, D., Bica, C. I., & Cavalu, S. (2024). The effects of SGLT2 inhibitors in patients with metabolic dysfunction-associated fatty liver disease: A narrative review. Journal of Mind and Medical Sciences, 11, e00009.
Shiba, T., & al., et. (2022). Antifibrotic effect and long-term outcome of SGLT2 inhibitors in patients with NAFLD complicated by diabetes mellitus. Hepatology Communications, 6(11), 3073–3082. https://doi.org/10.1002/hep4.2069
Wei, Q., Xu, X., Guo, L., Li, J., & Li, L. (2021). Effect of SGLT2 inhibitors on type 2 diabetes mellitus with non-alcoholic fatty liver disease: A meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 12, 635556. https://doi.org/10.3389/fendo.2021.635556
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2019). Global epidemiology of nonalcoholic fatty liver disease Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 64(1), 73–84. https://doi.org/10.1002/hep.28431
Zhang, X., Liu, Q., Zhao, S., & Wang, Y. (2024). Parental Neglect and Social Media Addiction of Adolescents: The Chain Mediation Effect of Basic Psychological Need and Personal Growth Initiative. Journal of Adolescence, 98, 45–56. https://doi.org/10.1016/j.adolescence.2024.01.004
Zhou, J., Sun, D.-Q., Targher, G., Byrne, C. D., Lee, B.-W., Hamaguchi, M., Kim, S. U., Hou, X., Fadini, G. P., Shimabukuro, M., Furuhashi, M., Wang, N.-J., Tilg, H., & Zheng, M.-H. (2023). Metabolic dysfunction-associated fatty liver disease increases risk of chronic kidney disease: A systematic review and meta-analysis. EGastroenterology, 1, e100005. https://doi.org/10.1136/egastro-2023-100005
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Anak Agung Ngurah Oka Parama Wangsa, Ni Komang Ayu Diah Suryandari
This work is licensed under a Creative Commons Attribution 4.0 International License.
Hak cipta pada setiap artikel adalah milik penulis.
Penulis mengakui bahwa SEHATRAKYAT (Jurnal Kesehatan Masyarakat) sebagai publisher yang mempublikasikan pertama kali dengan lisensi Creative Commons Attribution 4.0 International License.
Penulis dapat memasukan tulisan secara terpisah, mengatur distribusi non-ekskulif dari naskah yang telah terbit di jurnal ini kedalam versi yang lain, seperti: dikirim ke respository institusi penulis, publikasi kedalam buku, dan lain-lain. Dengan mengakui bahwa naskah telah terbit pertama kali pada SEHATRAKYAT (Jurnal Kesehatan Masyarakat).
